I totally agree. What seems odd to me is that MEDI has remained very strong these last 4 or so months somewhat on expectations for MEDI-507. Indeed, that compound has been the focus of about 1/2 of all MEDI press releases since April. And MEDI's current uptrend (which may have broken the last few weeks) actually began on the back of an April 2 news release about initiating Phase II clinical trials for MEDI-507 in Psoriasis patients. On that day MEDI was at 30. Now MEDI does have other compounds in development (like Vitaxin, etc...), but MEDI-507 seems to be the most exciting from the Street's point of view.
All this said, and at the risk of sounding like a broken record, beside MEDI-507 (which, like a lot in development, can be a huge winner or a complete bust), BTRN has AlloMune, ImmunoCognance, and XenoMune in preclinical testing with Novartis Pharma AG, and more (including 30% of Stem Cell Sciences -- just a thought -- seems SCS should actually benefit from a rejection of Federal Stem Cell funding as they are already located outside the US (for the most part, anyway). Complete platforms, not just individual compounds. Do they have any value whatsoever? Despite the Novartis joint venture, Street doesn't seem to think so. At least not yet. At some point I suspect this company will get the attention of some smart institutions. Until then, it appears, just Chinese water torture |
